EP4176873A1 — Urinary symptom therapeutic agent
Assigned to Taiho Pharmaceutical Co Ltd · Expires 2023-05-10 · 3y expired
What this patent protects
The present invention addresses the problem of providing a voiding symptom therapeutic agent for lower urinary tract disorders accompanied by residual urine. The present invention provides a voiding symptom therapeutic agent for lower urinary tract disorders with a residual urine…
USPTO Abstract
The present invention addresses the problem of providing a voiding symptom therapeutic agent for lower urinary tract disorders accompanied by residual urine. The present invention provides a voiding symptom therapeutic agent for lower urinary tract disorders with a residual urine volume of 50 mL or more, the therapeutic agent containing 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexen-1-one or a salt thereof as an active ingredient.
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.